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Abstract
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Introduction
Human immunodeficiency virus type 1 (HIV-1) is a recently
emerged human virus that over the past thirty years has ignited
the worldwide AIDS pandemic [1]. Extensive characterization of
the viral enzymatic machinery has led to a collection of drugs
that inhibit each of the respective activities of these proteins and
when used in combination have curtailed overt viral replication in
infected individuals [2]. Despite these advancements, patients
undergoing these therapeutic regimens can develop drug resistant
viral strains leading to higher viral loads and further disease
progression. Identification of new viral and/or host drug targets
is warranted to place further barriers to new cycles of viral
replication.
To understand the complex processes involved during viral
infection, we assert that it is beneficial to consider all available
knowledge to effectively select targets for therapeutic intervention.
These include molecular information about protein sequence
and structure, protein-protein interactions, protein modifications,
protein localization, protein domains and phylogenetic informa-
tion. Several databases have emerged which focus on subsets of the
aforementioned areas and are routinely used by scientists to study
HIV [3–7].
These and other bioinformatic databases and applications
generally focus on a specific area of knowledge, and are federated
with some information from other databases. These segregated
data sources likely limit the ability to investigate and understand
complex biological systems. Here, we compile existing informatics
relating to HIV-1 infection into an intuitively accessed database.
We propose that integrated data management has distinct ad-
vantages over existing data repositories in hypothesis-generated
science and experimental interpretation. We have built HIVTool-
box, a database/web application that integrates information about
HIV protein sequence, structure, and function. This tool facilitates
hypothesis generation, experimental design, and interpretation as
demonstrated by example analyses of HIV integrase.
Results
Examples of analyses with HIVToolbox
To demonstrate different types of analysis supported by
HIVToolbox, integrase (IN) was analyzed as a case study. IN
is a well-studied multidomain and oligomeric viral protein that is
essential for integrating viral DNA into the host genome, for viral
infectivity, and for which potent inhibitors of its strand transfer
function are chemotherapeutically available. Examples of how
HIVToolbox can assist with hypothesis generation, experimental
design, interpretation of results, and evaluation of structures
and structural models are in Figs. 1–4, Table 1. One of the
advantages is that data from many separate studies can be readily
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e20122interpreted simultaneously. Several new hypotheses concerning IN
complexes, DNA binding, nuclear import, and LEDGF binding
are discussed. Since there is no structure of full length IN, these
analyses also involved a number of different IN structural models
that were generated by superposition of common regions in
experimental IN structures (see Methods). This is an approach
that was previously used by Wang et al. to propose a structure of
the full IN monomer [8]. The models are available on the
Figure 1. Analysis of Integrase with HIVToolbox. (A–C) Output of HIVToolbox showing relationships of IN elements shown in a model
constructed from superposition of the catalytic domains in structures 1EX4 and 1K6Y. Residues 1–7, 47–55, 140–148, and 270–288 are unstructured
and not shown. The left panels shows domains [NTD (red), CCD (Blue), and CTD (green)] and minimotifs; the center panels show functional sites and
protein-protein interactions the right panels shows residues that are .98% conserved in 3787 HIV-1 IN isolates (yellow). (A) Location of three of the
four putative CK2 phosphorylation sites located on the surface of the IN CCD (left panel); the 4
th CK2 site is in the CTD unstructured region. Numbers
indicate the positions of putative phosphorylation sites. D270 is the last residue in the structure (orange). Conservation of the residues on CK2 sites is
shown in Table 1.( B) Conservation and location of the dimerization interface(s). Residues at the dimerization interface less than 3.25 A ˚ from atoms
in the other chain are colored: (red, 1EX4), (cyan, 1WJA), and (lighter cyan, 1K6Y). (B, C) Conservation and location of protein-protein interaction sites,
modification sites, and DNA binding sites. (C) is a 180u rotation of (B) about the z-axis. (A, B, C) Sites are colored: DNA binding=green, Importin 7
binding=dark purple and dark green, Zn binding=purple, Karyopherin a5 binding=teal and orange, LEDGF binding=teal, Lysine acetylation=dark
green, proline isomerization=orange, active site=royal blue, reverse transcriptase (RT) binding=brown.
doi:10.1371/journal.pone.0020122.g001
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the Prototypic Foamy Virus IN (PFV IN) to create a HIV-1 IN
model, and analyzed this model with HIVToolbox [9].
Examination of the residues making contacts in different dimer
structures of HIV-1 IN reveals that the relevant residues are
largely clustered on one face of IN and are .98% conserved in
3787 IN sequences from the Los Alamos HIV Sequence Database
(Fig. 1A) [8,10,11]. It is thought that dimeric IN is responsible for
the 39-processing activity in which IN removes 2 nucleotides from
each end of the LTR in a reaction that primes a nucleoprotein
complex (the intasome, the viral DNA genome and tetrameric IN)
for the subsequent strand transfer reaction leading to integration
and establishment of the proviral state [12]. When we examine the
IN dimeric unit there are several features that are likely highly
relevant to this activity.
A number of different studies have identified different sets of IN
residues that bind DNA [10,13–21]. Mapping all DNA binding
residues onto the structures of IN shows a cluster of DNA binding
residues near the active site (Fig. 1C). However, there are several
other scattered clusters throughout IN. Comparison of the
structure of the IN dimer shows that DNA binding residues in
this binding groove continue into the juxtaposed catalytic domain
of the dimer (Fig. 2A). The continuity of these additional DNA
interacting residues (D207, K111, K136, E138, K215) [RefSeq:
NP_705928] only becomes apparent in the dimer. In the
IN:LEDGF hetero-tetramer model, LEDGF helps to define a
putative DNA binding groove with a diameter of ,25 A ˚, similar
to the size of double stranded DNA (Fig. 2B, arrowheads). As
previously observed a second cluster of DNA binding residues is
located in the C-terminal domain (CTD) [14–17,21]. Since the
dimer is active in hydrolysis of the viral LTRs, these DNA binding
residues are likely involved in binding the viral DNA as previously
proposed in a number of models.
Analysis of IN with HIVToolbox also reveals that there is a
striking overlap of clusters of DNA binding residues with several
nuclear import motifs (Figs. 1B, 1C, 2C). Karyopherin a5 binds
three regions on the surface of IN dimers [22,23]. One of these
sites overlaps almost entirely with the LEDGF binding site,
whereas the other nuclear import sites overlap with DNA binding
sites (Figs. 1B, 1C, 2C), thus competition for these sites would
be expected. Importin 7 binding requires two sites in the CTD;
analysis with HIVToolbox reveals that these sites overlap with the
cluster of residues that bind the viral LTR [24]. Consistent with
the overlapping sites, the levels of viral genome are reduced .50%
when the Importin 7 motifs are mutated [19]. However, analysis
with HIVToolbox reveals that one of the Importin 7 sites overlaps
Figure 2. Analysis of Integrase model dimers hetero-tetramers. Output of HIVToolbox showing spatial positions on surface plots of different
function sites on IN structural models in the same orientation. (A) Models of IN dimers showing domains (left panel), several functional sites (middle
panel) and residues .98% conserved (right panel, yellow). In the left panel the yellow numbers indicate the monomer subunit for each domain. In
the middle panel residues are colored as follows: DNA binding residues=green, tetramerization residues=blue, active site residues=royal blue (B)
IN:LEDGF hetero-tetramer showing LEDGF domains (grey) and proposed viral LTR binding groove (arrowhead) (C) IN dimer showing nuclear import
motifs.
doi:10.1371/journal.pone.0020122.g002
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karyopherins on binding of viral DNA needs to be considered
in interpretation of their effects on nuclear import and binding
LEDGF. This relationship becomes clear when HIVToolbox is
used for interpretation. Nup153 is also implicated in nuclear
import of IN, but its binding site within IN is not yet known [25].
The spatial arrangement of the nuclear import motifs on the
surface of the IN dimer is striking. The five known nuclear import
motifs are spatially contiguous like a ‘zipper; along the surface of
the dimer, with two Karyopherin a5 sites located on one subunit,
in trans with one Karyopherin a5 and two Importin 7 motifs on
the other subunit (Fig. 2C). Some Karyopherin sites in these
subunits are buried in the IN tetramer; however, two of the 5-
motif zippers are located along the surface.
While Karyopherin a5 and Importin 7 both serve roles in
nuclear import, they likely would compete with binding of IN to
the HIV-1 LTR and to LEDGF. Presumably, these karyopherins
would block these functional sites in the cytosol, but become
activated after import of IN into the nucleus. It is not surprising
given so many IN nuclear import motifs, which are likely
redundant, that a recent re-evaluation found none to be required
for nuclear import [26].
Summarizing these analyses with HIVToolbox suggests that it
is important to determine 1) if LEDGF competes with Karyo-
pherin a5 for binding IN, 2) if Importin 7 and/or Karyopherin a5
compete with binding of viral LTRs and 3) the stoichiometry of
binding of IN dimers and tetramers with LEDGF and importins
and how this is affected by DNA binding.
Figure 3. Analysis of Integrase model tetramers and hetero-octamers. Output of HIVToolbox showing surface plots of IN structural models.
(A, B) IN tetramers showing domain organization (left panels) and locations of actives site residues (royal blue), proposed viral DNA binding grooves
(yellow lines), proposed genomic DNA binding channel (red line), and zinc binding sites (cyan). Yellow numbers indicate the subunit too which the
domain belongs. (C) IN:LEDGF hetero-octamers models showing organization of proteins (left panel) and proposed DNA binding groove (middle
panel, red line). LEDGF subunits are colored grey. (D) An end-on view of the proposed host DNA binding channel in the IN:LEGDF hetero-octamer
model shown in (C) (red circle).
doi:10.1371/journal.pone.0020122.g003
Figure 4. A model of IN:LEDGF:viral DNA based on the PFV IN structure. (A) A model of HIV-1 IN complex with 4 IN subunits, 4 LEDGF
subunits (light gray), and two viral DNA strands (dark gray); (A, B) Left panels (IN NTD=green, CCD=blue, CTD=red. (A, B) Right panels show
functional sites (green=DNA binding), red=dimerization interface in 1EX4 [10], cyan=dimerization interface in 1WJA [11]; blue=tetramerization
interface in 1K6Y [8]; purple=zinc binding site [11]; brown=reverse transcriptase binding site [31], light brown=tetramerization residues [16]. (B)A
90u rotation about the Y-axis of A. Orange arrowhead indicated channel proposed to bind target DNA [36].
doi:10.1371/journal.pone.0020122.g004
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primed LTRs undergo a symmetric nucleophilic attack on the host
DNA, integrating the viral DNA [8]. Reparation of the two 5
nucleotide gaps of host DNA flanking the proviral DNA insert
and the two nucleotides of unjoined viral DNA left after a
successful integration event is catalyzed in vivo by the host DNA
repair machinery, restoring the integrity of cellular genome. Our
IN tetramer model contains an asymmetric dimer of dimers, a
symmetry evident from the 1K6Y structure [8]. The residues
involved in tetramerization in 1K6Y are also well conserved in
.97% of the IN sequences in HIVToolbox (Figs. 1A, 1B). The
asymmetry of the tetramer is evident by comparing Fig. 3A with
3B, which are flipped 180u with respect to each other. In Fig. 3A,
the two active sites are on opposing sides of a channel lined with
some DNA binding residues and separated by ,17 A ˚ along the
channel, perfectly spaced to excise a 5 bp fragment of DNA, the
known product of the strand exchange reaction. The two grooves
in the dimer proposed to bind the viral LTRs (Fig. 3A, yellow
line) are aligned nearly perpendicular to proposed DNA binding
channel. When this molecule is flipped (Fig. 3B) the other two
active sites in the tetramer can be seen and are separated by 74 A ˚;
there is no obvious channel that could accommodate the host
DNA.
LEDGF binds to IN and is known to play a role in selecting
sites of integration in the human genome [27]. To explore this
interaction, an IN:LEDGF hetero-octamer model was generated
by superposition of the CCD domain of IN in the LEDGF:IN
complex with the CCD domains of IN in our model tetramer
as done for other IN models [8,28]. In addition to lining the
groove in the dimer (Fig. 2B), LEDGF also extends the DNA
binding channel proposed to bind the host DNA (Fig. 3C, 3D).
Although LEDGF is not critical for the integration reaction,
positively charged LEDGF residues R404, R405, K407, and
K424 in LEDGF line the proposed DNA binding channel and
may play a role in chromosomal site selection in the host
genome, consistent with its known effects on selectivity for the
site of integration [27]. The LEDGF binding site in IN is highly
conserved with the exception of D167, which has a conservative
substitution of E in 19% of IN sequence [29,30]. Alternatively,
this high sequence conservation could also be due in part to the
binding site for Karyopherin a5, which overlaps with the binding
site of LEDGF.
Table 1. Sequence conservation of CK2 sites in different strains of HIV-1.
CK2 sites in IN –
[ST]XX[DE] – DOMAIN
Site 1: 66–69 –
THLE – CATALYTIC
Site 2: 93–96 –
TGGE – CATALYTIC
Site 3: 195–198 –
SAGE – CATALYTIC
Site 4: 283–286 –
SRQD – C-TERMINAL
HIV-1/M (3787 isolates) [ST ] T -99% T-99% S-96%; C-1%; V-1%; T-2% G-49%; S-49%; V-1%
[DE] G-1%; E-99% E-96%; D-2% K-1%; E-98% V-1%; T-1%; D-94%; N-3%;
E-1%
A (20 isolates) [ST ] T-100% T-100%; S-100% G-81%; S-14%; D-5%
[DE] E-100% E-100% E-100% D-95%; N-5%
A1 (149 Isolates) [ST ] T-99%; N-1% T-99%; N-1%; L-1% S-93%; V-1%; T-5% G-71%; S-26%; M-2%; D-1%
[DE] S-1%; L-1%; E-98%; Q-1% G-1%; T-1%; E-97%; Q-2% E-98%; G-1%; C-1% D-90%; N-6%; E-1%;
B (1443 Isolates) [ST ] T-99% T-99% S-96%; C-1%; T-1% G-9%; S-89%; M-1%; R-1%
[DE] E-99%; G-1% D-1%; E-98% G-1%; D-1%; E-98% D-95%; N-2%; E-1%
C (544 Isolates) [ST ] T-99% T-99% S-97%; C-1%; V-1%; T-1% G-87%; S-9%; V-1%; D-2%
[DE] E-99% G-1%; D-3%; E-96% G-1%; K-1%; E-98% G-1%; M-1%; D-96%; N-2%
D (85 Isolates) [ST ] T-100% T-100%; S-98%; T-1% G-5%; S-94%;
[DE] G-2%; E-98% D-1%; E-99% E-99%; R-1% D-98%; N-1%
F (3 Isolates) [ST ] T-100% T-100% S-100% G-75%; S-25%
[DE] E-100% E-100% E-100% D-75%; N-25%
F1 (39 Isolates) [ST ] T-98%; K-3% T-98%; Y-3% S-98%; I-3% G-88%; S-10%
[DE] E-98%; W-3% D-13%; E-88%; T-3%; E-98% D-90%; N-8%
F2 (8 Isolates) [ST ] T-100% T-100% S-100% G-78%; S-11%
[DE] E-100% E-100% E-89%; *del-11% D-100%
G (49 Isolates) [ST ] T-100% T-100% S-100% G-88%; S-12%
[DE] E-100% E-98%; Q-2% E-100% D-96%; E-4%
H (5 Isolates) [ST ] T-100% T-100% S-100% G-50%; S-50%;
[DE] E-100% E-100% E-100% E-100%;
J (6 Isolates) [ST ] T-71%; *del-29% T-71%;*del-29% A-29%; S-71% G-57%; S-14%; P-14%;
Q-14%;
[DE] D-29%; E-71% E-71%; *del-29% G-29%; E-71%; G-14%; D-71%; Q-14%;
K (2 Isolates) [ST ] T-67%; R-33% T-100% S-67%; L-33% G-33%; S-33%;
[DE] M-33%; E-67% G-33%; E-67% E-67%; Q-33%; D-67%;
*‘del’ indicate that the residue is deleted or was not present in one or more structures.
doi:10.1371/journal.pone.0020122.t001
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bind LTRs and that dimerization of these dimers brings the viral
genome ends together and allows binding of the tetramer to the
host genome for initiation of the strand transfer exchange [8]. In
this model, the control of dimer tetramerization may be an
important aspect of IN function. By using HIVToolbox, we can
look for other IN elements that overlap with the residues that
are involved in the tetramer interface to generate new
hypotheses. HIV-1 reverse transcriptase binds to the CTD of
IN, a region that is juxtaposed to L241 and L242, residues
known to block tetramerization [16,31]. K258, a residue that
binds reverse transcriptase, is also acetylated and thus could be
involved in controlling the release of RT and the multi-
merization state of IN [8,32]. Collectively, these analyses reveal
the power of HIVToolbox in generating new hypotheses,
evaluating structural models, and interpreting experiments for
a well-studied protein.
Analysis of a HIV-1 IN model based upon the Prototypical
Foamy Virus integrase structural model
The Prototypic Foamy Virus (PFV) IN model with viral DNA is
based on the structure of a 3 domain IN PFV monomer dimerized
with an IN catalytic domain and bound to viral DNA [33]. We
used this structure to build a model of the HIV-1 IN tetramer
bound to viral DNA [33]. The PFV model is gaining acceptance
among scientists, but there are a number of issues that need to be
reconciled if this is indeed a structural architecture that is
representative of HIV-1 IN: 1) The center channel that is
proposed to bind the target DNA is only 12–13 A ˚ wide at some
points (e.g. R231-R231) and the double helix of the target DNA
has a diameter of 20 A ˚. Furthermore, the linker between the CTD
and CCD of HIV-1 IN is 6 residues shorter than in the PFV IN.
Considering that the CTD linker is a fully extended helical
conformation in the structure of the PFV IN, and that this
extended conformation of the CTD is important for forming the
central DNA binding channel in the PFV IN tetramer, it does not
seem likely that the domains of HIV-1 could assume this structural
configuration.
We generated a tetramer model of HIV-1 IN with two viral
DNA fragments, by superposition of the HIV-1 and PFV domains
and superposition of the structure of the LEDGF:IN complex;
interdomain linkers were ignored in this model (see Methods;
Fig. 4). Analysis of the PFV-based IN model with HIVToolbox
also shows: Only one of many DNA binding residues in HIV-1 IN
maps to the viral DNA binding site or the proposed DNA binding
channel in PFV IN (Fig. 4A, 4B, right panels). The LEDGF
binding site in this model is not positioned where it could make
contacts with the target DNA. Further analysis with HIVToolbox
shows that the LEDGF HIV-1 IN binding site (residues 161–174)
is highly conserved in greater than .97% of the 3787 viral
sequences in HIVToolbox with the exception of D167 (which
has a conservative substitution of E), and K173 (which has a
conservative substitution of R). This site is not conserved in PFV
IN (residues 250–263 in HFV IN) [UniProt: P14350]. Considering
the 3D location of the analogous LEDGF binding site in HIV-1 IN
and that PFV IN does not bind LEDGF, it is difficult to envision
how LEDGF could affect the sites of HIV-1 DNA integration if IN
is structured as in the PFV-based model [9,30,34,35].
Based on these observations we must consider the possibility
that while the integration reaction is conserved, the oligomeric
structures of the catalysts may differ between HIV-1 and HPV.
The TN5 transposase has a different tetramer structure and the
PFV IN and may also have a structure of its active tetramer that is
distinct from HIV-1 IN [36,37]. However, since Raltegravir and
Eltegravir both bind PFV Integrase and block strand transfer, it is
likely that the binding of the viral DNA ends in both PFV and
HIV-1 INs are similar [36].
Alternatively, differences in the HIV-1 and PFV structures may
represent differences between those states required for completion
of the IN reactional set. Our new model is based on the apo form
lacking DNA, while the HFV model in complex with viral DNA.
There are also several possible intermediates in the strand transfer
reaction. None of the existing models, including ours, is consistent
with the recently determined low-resolution electron microscopy
(EM) tomography image of the HIV-1 IN tetramer: DNA complex
[38]. This could again reflect that the EM images were of IN
tetramers bound to a strand exchange intermediate different than
the aforementioned models. While we have not assessed a number
of previous IN models, these models can be readily added to
HIVToolbox for relational assessment. This analysis shows how
useful HIVToolbox is in evaluating structural models.
Integrase is phosphorylated by Casein Kinase 2 (CK2)
Since HIVToolbox maps the ,5000 minimotifs from Minimo-
tif Miner, new functional elements in HIV-1 proteins can be
identified [10,11]. CK2 has been reported to phosphorylate HIV-
1 matrix, Rev, and Vpu proteins in vitro, but is not known to
phosphorylate IN [13,39,40]. Other labs have predicted mini-
motifs in HIV-1 proteins [41–43]. IN contains four putative CK2
consensus phosphorylation sites (T66, T93, S195, S283) [RefSeq:
NP_705928]. Phosphorylation assays of recombinant His-tagged
IN were performed using commercially obtained purified re-
combinant human CK2 (New England Biolabs) in the presence of
32P-c-ATP. Serial dilution of CK2 showed phosphorylation of
recombinant HIV-1 IN substrate with as little as 0.02 U/mL of
kinase (Fig. 5A).
We next examined which IN domains were phosphorylated
by CK2. Recombinant IN and individual domains fused with
GST were purified and subjected to CK2 phosphorylation assays.
The full length IN(1–288) gave the strongest signal for phosphor-
ylation when compared to N-terminal domain [NTD, IN (1–50)]
and the catalytic core domain [CCD, IN (1–212)], both of which
were weakly phosphorylated (Fig. 5B). IN (212–288) CTD
was phosphorylated to a level comparable to that of the full-
length IN (1–288). Reactions with control GST or lacking
substrate (- control) showed no significant phosphorylation. These
domain-mapping experiments indicate that IN CTD is the
primary target of CK2 phosphorylation.
To further investigate the sites of IN CK2-mediated phosphor-
ylation, we generated all possible permutations of Ser/Thr to
Ala point mutations in the 4 putative CK2 phosphorylation sites
(T66, T93, S195, S283). His-tagged IN and these mutants were
purified, normalized for their protein content, and tested in kinase
reactions using purified CK2. The S283A substitution severely
compromised CK2 phosphorylation, reducing it by 90% when
compared to wild type IN, whereas other mutants were without
effect (Fig. 5B, 5C). Phosphorylation of S283 was also reflected
in an analysis of all double, triple, and quadruple mutants for
the potential CK2 phosphorylation sites (data not shown). Only
those mutants which had a S283A mutation showed reduced
phosphorylation of IN. When the S283A mutation was intro-
duced into the IN (212–288) CTD fusion protein, this also reduced
the majority of IN phosphorylation when compared to full length
IN (Fig. 5B). The data indicate that S283 is the principal in vitro
CK2 phosphorylation site in IN. Despite efficient phosphorylation
of S283 in vitro, mutation of this phosphorylation site (S283A) in
a recombinant virus showed no impairment of IN nuclear import,
syncytia formation, or detectable accumulation of p24 when
HIVToolbox, an Integrated Web Application
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shown), nor when the C-terminal amino acids containing the CK2
consensus minimotif (275–288) were deleted [44] (data not shown).
Interpretation of CK2 phosphorylation sites in integrase
Since one purpose of HIVToolbox is to assist with interpreta-
tion, the CK2 sites within IN are discussed within this context.
The CK2 site at 283–286 was phosphorylated by CK2. These
residues were poorly conserved in the IN sequences of 3787
isolates, as determined with a position-specific scoring matrix
(PSSM) in HIVToolbox. However, when we examined conserva-
tion in different strains, IN 283–288 was highly conserved in
.1500 viruses from Group M, clades B and D (Table 1). One
interesting observation was that the CK2 consensus sites that were
not phosphorylated were highly conserved. The group/clade
analysis of the CK2 phosphorylation sites in HIV-1 IN can be
performed for any sequence element of interest by using the strain
selection function and sequence alignment section in HIVTool-
box. A more complete description on interpretation of these CK2
sites in different HIV-1 groups and clades is shown in Table 1.
Examination of the spatial relationship of this CK2 phosphor-
ylation site to other functional IN regions shows this site is in an
intrinsically unstructured segment on the C-terminus extending 18
residues from D270, the last structured residue in 1EX4. In
the structure of the IN monomer the phosphorylation site would
be expected to lie away from the active site and likely only have
access to some lysine acetylation sites and some of the DNA
interacting residues [32,44–46], which is in agreement with its lack
of impact on viral replication upon deletion (unpublished data, M.
A. Muesing). However, it is noteworthy that in our IN tetramer
model the disordered fragment containing the CK2 site is well
positioned to sit in the channel that is lined with DNA binding
Figure 5. Integrase is phosphorylated by CKII on serine 283. (A) Phosphorylation of IN by CK2. Reactions containing IN,
32P-c-ATP and CK2
were serially diluted 1:3 starting from 50 U/mL (right lane). The extent of phosphorylation was visualized by SDS-PAGE and autoradiography. (B)
Phosphorylation of IN domains by CK2. Reactions as in A and contained purified GST-IN or GST-IN domains as indicated in the diagram. IN(S283A) is a
point mutation of one of the putative CKII phosphorylation sites. (C) His-tagged point mutants of putative CKII sites within IN were phosphorylated
by CK2 as in (A). A control reaction lacking IN showed no phosphorylation (not shown). Reduced phosphorylation of S283A mutant is indicated (*).
Samples were normalized for protein concentration.
doi:10.1371/journal.pone.0020122.g005
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subunits. One possibility is that this unstructured region is not
disordered in the tetramer and blocks the DNA binding channel
before IN is transported into the nuclear compartment. This may
help to repress access to other molecules, but would likely be
dispensable in assays that assess replication, as was previously
observed [44] (data not shown). Alternatively, this CK2 site might
have some functional role in a select set of virus/host interactions,
as it seems like the site is selected against except in the case of M/B
and M/D viruses. The surrounding residues in the unstructured
region are .93% conserved in the 3787 isolates, whereas only the
consensus residues for the CK2 site are poorly conserved. Since
the coding sequence for IN residues 271–288 overlaps with the
code for amino acids 1–18 of the Vif amino-terminus, the con-
sequence of these observations should also be considered with
respect to Vif functionality. However, regardless of the identity of
the amino acid specified at IN 283 (either serine or glycine), the
corresponding amino acids in Vif (Q12/V13) are invariant in all
HIV-1 clades.
The other CK2 consensus sites at 66–69, 93–96, and 195–198
were highly conserved in .98% of 3787 isolates, sometimes
having conservative D/E or S/T substitutions that conserve the
[ST]xx[DE] minimotif (Table 1). These sites were not signifi-
cantly phosphorylated in vitro. Examination of IN structures
showed that these sites are on the surface of the monomeric unit
(Fig. 1A). The sites at 66–69 and 93–96 are also on the surface of
both experimental [8,10] and our model structures of IN (Fig. 1A);
however, the site at 195–198, is buried in model dimers and
tetramers. Thus, it is conceivable that this site may not have been
phosphorylated in vitro, if the assay contained multimerized IN,
and we cannot thus rule out that IN monomers may also be
phosphorylated at this position.
Design and Implementation
HIVToolbox model and database construction. The
knowledge domain we sought to model was that of HIV-1
proteins, including sequences, structures, functions, and func-
tional interactions with other small ligands and macromo-
lecules. We generated a model for sequence, structure, and
function of HIV-1 proteins. This model includes RefSeq and
isolate sequences for the 24 HIV-1 proteins, strain classifications,
protein structures, protein subcellular localizations, virus-host
protein interactions, requisite host proteins, and the cellular and
Figure 6. Entity Relationship diagram of HIVToolbox model as a MySQL database. Boxes show different tables (titles listed on top row)
and a description. Foreign keys between tables are shown.
doi:10.1371/journal.pone.0020122.g006
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proteins (Fig. 6).
HIVToolbox was built as a MySQL database importing and
integrating data from existing databases, with the data sources
shown in Table 2. Integration of these data required a number of
manual and computational annotation efforts, as well as comp-
utational processing of some of the data into new tables as follows:
The publications for all tuples of the HIV-1 protein-protein
interaction database were reviewed to identify and re-annotate
the interacting residues on the HIV-1 protein in those entries where
this information was known. Alias lists for HIV-1 proteins were
generated from databases and the primary literature. Minimotifs
from the primary literature were annotated to identify experimen-
tally confirmed HIV-1 minimotifs. Several models of HIV-1
proteins were created by superposition of atoms in structures that
had common regions. Data for host proteins that are required for
the HIV-1 life cycle were annotated from several RNAi screens
reported in the primary literature. Functional sites in HIV-1
proteins for interaction with other HIV-1 proteins, other macro-
molecules, metals, etc., as well as localization of HIV-1 proteins
were annotated from both external databases and the primary
literature. Sequence alignments of all HIV-1 protein isolate se-
quences in the database were performed for each HIV-1 protein, as
well as for different groups and clades. These alignments were used
to generate position specific scoring matrices that are stored in the
HIVToolbox database. Variable sequence numbering frames used
for RefSeq sequences and PDB sequences were computationally
matched and stored in the database. Statistics for the data in the
HIVToolbox database are summarized in Table 3. Parsers were
built for all imported databases and can be used to frequently
update the data in HIVToolbox.
Construction of HIVToolbox web application. HIVToolbox
is a web-based application built as a Java 2 Enterprise Edition
servlet that pulls data from a server-side MySQL relational database.
The application retrieves data from tables of the database (Fig. 6)
and stores the data in a number of ‘‘beans’’, Java objects that
correspond to query results of data in the tables of the database. Beans
are easily stored and retrieved by the application. The majority of
the application’s data processing and calculations are performed
on the server to minimize time transmitting data over the internet
to the end user. The overall architecture of HIVToolbox is shown
in Fig. 7.
HIVToolbox incorporates the results of several open-source
utilities.Java2EnterpriseEdition[http://www.java.com],anopen-
source web application development tool and language, provides
the framework of the application. MySQL [http://www.mysql.
com], an open-source relational database system, is used to store
and retrieve the considerable data that are required to run
HIVToolbox. Apache Tomcat [http://tomcat.apache.com], an
open-source web application server, is used to serve HIVToolbox.
Jmol [http://www.jmol.org], an open-source Java molecular
viewer, is used to view the protein structures. MooTools [http://
mootools.net], an open-source JavaScript library, powers the con-
servation slider. ClustalW [http://www.clustal.org], an open-source
Table 2. Sources of data in the HIVToolbox MySQL database.
Table Name Data Type Source
hiv_protein_annotation Annotations for HIV-1 proteins and effects on host proteins NCBI/PubMed; NCBI/Protein [6]
hiv_protein_sequence_conservation List of each residue in HIV-1 proteins and associated conservation
in existing data
Self-generated from NCBI/RefSeq data
[6]
hiv_protein_sequence_feature List of interesting sites on HIV-1 proteins (sites for dimerization,
binding, cleavage, etc.)
NCBI/PubMed; HIV PPI database;
*RCSB/PDB [3,6,56]
ref_group HIV-1 groups and accession numbers NCBI/RefSeq [6]
ref_hiv_isolates_pssm Position-specific scoring matrix data generated by ClustalW from
HIV-1 isolate sequences.
Calculated from Los Alamos/HIV and ;
NCBI/PubMed [6,10]
ref_hiv_protein_alias HIV-1 proteins and synonym names NCBI/PubMed [5]
ref_hiv_protein_domain List of domains in each HIV-1 protein and location of each domain
in its protein
NCBI/Conserved Domains [5]
ref_hiv_protein_interaction_residue List of interaction sites for HIV-1 proteins and residue positions for
each interaction site
NCBI/PubMed; HIV PPI database [4,5]
ref_hiv_protein_structure List of structures in HIV-1 proteins and data about each structure RCSB/PDB [56]
ref_hiv_protein_structure_chain Sequence information for structures of HIV-1 proteins RCSB/PDB [56]
ref_hiv_protein_structure_relative_position Positional information about structures of HIV-1 proteins NCBI/RefSeq; RCSB/PDB [5,56]
ref_host_protein List of HIV-1 host proteins, their sequences, and whether or not the
protein is required for HIV-1 replication
NCBI/RefSeq; Literature [5,57–60]
ref_host_protein_bio_mol_go_term List of term types used in HIV-1 databases GeneOntology AmiGO [33,61]
ref_isolate_hiv_protein_sequence List of HIV-1 isolates, their sequences, accession numbers, date and
country of infection, patient codes, and source database code
NCBI/Protein; Los Alamos/HIV [4,5]
ref_retroviridae List of retroviruses, accession numbers, and links to articles NCBI/Taxonomy [5]
ref_subtype List of subtypes of HIV-1 and associated group of subtype NCBI/Taxonomy [5]
ref_swissprot List of Swissprot IDs and associated gene symbols UniProt/UniProtKB [62]
ref_swissprot_pdb List of PDB ID’s and corresponding Swissprot IDs UniProt/UniProtKB; RCSB/PDB [56,62]
MnM database Predicted minimotifs Minimotif Miner [10,11]
*Sequence features that are multimerization interfaces were calculated in Molmol based on residues that were less than 3.25 A ˚ away from at least one residue in
another subunit [63].
doi:10.1371/journal.pone.0020122.t002
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align sets of protein sequences and create the PSSMs [47]. BioJava
[http://www.biojava.org], an open-source Java-based biology
library, is used to properly format amino acid sequences. STRAP
[http://www.bioinformatics.org/strap] is used for formatting
aligned protein sequences [48].
Finally, Minimotif Miner [http://minimotifminer.bio-toolkit.
com] is used to provide the minimotif data displayed in
HIVToolbox [49,50]. To calculate minimotif probabilities we
implemented a previously published algorithm [51]. Since the
minimotifs displayed in the sequence windows are predictions
based on conserved consensus sequences and instances, the
Minimotif Log window displays a probability that the predictions
are correct. This calculated probability is based on a portion of the
sig score algorithm [51]. Briefly, the probability p1+ that a given
motif will occur at least once in a protein is calculated using the
formula:
p1z~1{(1{pmotif)
n
where n is the number of positions in the protein where the given
motif can occur, and pmotif is the probability of a particular motif
occurring at any given position in the protein. Further details on
the calculations of the p1+ value and the sig score algorithm can
be found in Davey et al [51]. It should be noted that the
frequencies of amino acid occurrences were derived from pre-
calculated values based on the human and HIV-1 proteomes;
probability values based on both proteomes are shown in the
application. Calculations based on the human proteome values
were included since HIV-1 must infect a human host cell to
replicate, and thus it may be useful to compare the probabilities
derived from both sets of amino acid frequencies.
User Interface and workflows. HIVToolbox processes and
presents this data in an easy-to-use open-access web application
(accessible at HIVToolbox [http://hivtoolbox.bio-toolkit.com]).
HIVToolbox was implemented as a website in order to minimize
usage barriers; a standalone application requiring downloading
and installation would discourage many prospective users from
trying HIVToolbox. In designing the application, we considered
common analysis workflows for investigating proteins. For
example, new functional regions can be identified by plotting
sequence conservation onto protein structure surfaces using tools
such as VENN, ConSurf, and Evolutionary Trace [52–54]. A
unified interactive view of protein sequence, structure, and
function was built and a schematic representation of the
software architecture is provided in Fig. 7.
The basic workflow for HIVToolbox is as follows: At the
application’s introductory webpage, users can select the HIV-1
protein they wish to investigate from a diagram of the HIV-1 life
cycle (Fig. 8). The application then displays the primary interface,
an interactive console from which the user can perform a variety
of functions related to the sequences, structures, and functions of
the selected protein (Fig. 9). Alternatively, the primary interface
page can be accessed directly via links in the HIV-1 protein
structure pages at the Protein Data Bank, which pre-loads the
selected structure.
The HIVToolbox viewer has four main integrated compo-
nents: a sequence viewer, an array of structural displays, two log
windows, and a sequence alignment section. Each window/
section/menu has a number of interactive features that trigger
coupled events in other application components. The sequence
viewer shows an HIV protein sequence that was selected from the
introduction page or navigation menu bar. The interaction of the
user with the program is shown in Fig. 7. Help pages and video
tutorials can be accessed by selecting the HIVToolbox icon at bio-
toolkit.com.
The main interface is shown in Fig. 9.The four main sections
are:
1. The Sequence Window displays the amino acid sequence
for the primary structure of the HIV-1 protein using IUPAC
single-letter amino acid abbreviations [55]. The sequence letters
are color-coded to indicate known domains in the protein, and
highlighted sequences indicate known functional sites such as
crucial residues for enzymatic activities, binding sites, multi-
merization interfaces, and post-translational modifications. Se-
quence regions for those structures that have been determined are
shown as a series of colored lines above the sequence; all known
structures for each HIV-1 protein are mapped in this manner.
Hovering the mouse pointer over any element displays metadata
in a popup balloon.
Selecting a structure line loads the associated structure into
three structure windows (discussed below); model structures are
indicated by dotted lines. Directly under the protein sequence,
horizontal thin black lines mark known host protein interaction
sites. Clicking a line causes the interaction site to be colored in
the appropriate structure window. Under the protein interaction
site lines are a series of figures representing putative minimotifs
predicted from consensus sequences or instances in the Minimotif
Miner database [http://minimotifminer.bio-toolkit.com] [49,50].
Selecting one of these figures colors it in both the sequence and
structure windows. Any number of minimotifs can be selected at
the same time. Selection of any of the features in the sequence
window loads an associated hyperlink to the log windows and
loads or colors the selected feature in one of the structure
windows.
2. The Structure Windows are comprised of three distinct
interactive three-dimensional structures of the HIV-1 protein
loaded in the Jmol molecular viewer, a 3D structural viewer that
runs as an applet within HIVToolbox. Each window displays an
interactive structure that can be zoomed or rotated and chains of
the structure can be selected for viewing from a set of checkboxes.
Table 3. Statistics for data in the HIVToolbox database.
Data type Number
HIV-1 proteins 24
HIV-1 residues 3137
HIV-1 protein isolate sequences 203,810
HIV-1 protein-protein interactions 313
HIV-1 experimental structures 621
HIV-1 experimental structure chains 1,356
HIV-1 model structures 6
HIV-1 model chains 34
HIV-1 protein domains 49
HIV-1 putative motifs 5,312
Experimentally determined motifs 198
Host proteins 2,096
Required host proteins 755
HIV-1 protein functional elements mapped 560
HIV-1 isolates with homology data 153,000
HIV-1 position specific-scoring matrices 104
doi:10.1371/journal.pone.0020122.t003
HIVToolbox, an Integrated Web Application
PLoS ONE | www.plosone.org 11 May 2011 | Volume 6 | Issue 5 | e20122Several standard Jmol structure analysis functions are accessible
through a mouse right click. Hovering the mouse over any part of
the structure reveals the residue and its number in the sequence.
The three windows are synchronized so that the user is always
viewing the same portion and orientation of the structure with
respect to the other two structure windows.
Figure 7. Diagram of software architecture of HIVToolbox.
doi:10.1371/journal.pone.0020122.g007
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compared: The Motifs/Domains window displays minimotifs and
domains of the loaded structure, coloring the sections of the
structure corresponding to the selected minimotifs and domains
appropriately. Linker regions are colored white. The Protein
Interactions/Sites window displays the functional sites colored
similarly to the highlighted positions in the sequence window.
Selection of any of the host-HIV-1 protein interaction sites colors
these residues in this window.
It is useful to visualize sequence conservation on protein
structure surfaces using tools such as VENN, ConSurf, and
Evolutionary Trace [52–54]. This function is implemented in the
Homology Structure window, which consists of a Jmol window
and a control panel directly beneath the window. The window
itself shows the conservation of the residues of the loaded structure.
The control panel beneath the window consists of a slider and
a text input box, allowing the user to select a desired conservation
percentage threshold. Initially, all residues are colored yellow,
indicating that they are all conserved, being above the 0%
conservation threshold. As the user moves the slider or changes the
percentage directly, residues that are not conserved in at least the
selected percentage of the isolates on record are changed to a blue
color; the number of isolates used for the calculation is shown.
The isolates selected can be interactively changed based on
species, group, and subtype selected from a navigation menu. This
display enables visual correlation of residue conservation with
putative minimotifs or other functional sites, enabling prediction of
important functional minimotifs in the virus. The Alignment
Section (described below) of HIVToolbox is tightly coupled with
this viewer.
3. The Information Windows consist of the Information Log
and Minimotif Log windows. The Information Log initially shows
a list of the domains and interaction sites the protein is known to
have; each feature is displayed in the color corresponding to that
particular feature in the Sequence and Structure windows. As the
user interacts with the Sequence Window (e.g., selects structures,
motifs, or interaction sites), the selections and colors representing
the selected elements are loaded into the Information Log. Further
Figure 8. Protein selection page of the HIVToolbox website. An image of the Introduction page of HIVToolbox is shown. Selection of any HIV-
1 protein name or protein object launches an interactive results page about the protein. A drop-down menu is provided for non-graphical access to
proteins.
doi:10.1371/journal.pone.0020122.g008
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its hyperlinked listing in the Information Log, taking the user to
a primary literature source for that feature. Additionally, the
Information Log can be hidden, and its contents can be cleared
or printed. The Minimotif Log displays information about the
putative minimotifs that have been found in the current protein;
when the user selects a minimotif in the Sequence Window,
information about the minimotif is loaded to the Minimotif Log.
Selection of hyperlinked minimotifs reveals additional information
in the Minimotif Log or opens a new browser with the primary
source for the minimotif.
4. The Sequence Alignment section consists of a window with
two tabs, the Alignment Tab and the PSSM Tab. The user selects
a set of isolates to work with by using three navigation pull-down
menus to select the species (HIV-1 or HIV-2), group (M, O, etc.),
and subtype (A, B, B/A recombinant, etc.) of the isolates in the
database. A display panel on the left shows a list of accession
numbers for each isolate in the selected set. It displays the total
number of isolates in the HIVToolbox database that match the
selected criteria. Clicking the ‘‘ClustalW Alignment’’ button after
selecting a set of isolates, retrieves a stored alignment calculated
via ClustalW, and a selection of aligned isolates are displayed in
the Alignment Tab [47]. The alignment of 20 randomly selected
isolates with the RefSeq and PDB sequences are shown.
Importantly, an alignment of the PDB sequence with the RefSeq
sequence with residue numbers allows direct comparison of
sequence and structural information, a limitation often faced by
biologists in routine experimental design and interpretation. A
calculated PSSM is available in the PSSM Tab for the selected
isolate set. In addition, the residues that are conserved above the
current percentage threshold selected in the Homology Structure
window’s slider are colored yellow in the structure window and
also highlighted in yellow in the PSSM display. An image of the
Sequence Alignment section is shown in Fig. 9.
Discussion
While several HIV databases have played a central role in
forwarding HIV research, these sources have some disadvantages.
The data is spread out among numerous sources, each providing
a different search interface with its own syntax, restrictions, and
output options. With the information spread out among multiple
sites, the results needed to address specific questions must often
be reformatted and pieced together, a barrier that discourages
investigation of many questions. Queries to these databases
generally return tables as results or have focused user interfaces
that can address a limited set of questions.
HIVToolbox rectifies these problems by consolidating relevant
information about HIV into one location, and presenting the
information to the end user in a single window consisting of an
easy-to-use graphical interface. This integration does not come
without a cost. The principle disadvantage of the integrated and
unified databases is that each individual domain of knowledge
is better maintained by a group of focused experts. Furthermore,
additional union tables are required for cross-referencing in-
formation retrieved from different databases. To address these
limitations, we rely on the domain experts of the individual
projects, and have built parsers and data miners that can be used
to keep the data current in HIVToolbox. Although not a perfect
solution, this methodology allows centralization of data while
keeping the data current.
We have shown the utility of HIVToolbox in experimental
design and interpretation by analyzing IN. HIV-1 has a very
complicated intracellular life and it is difficult to resolve its
functional pathways without an integrated tool such as HIV-
Toolbox that brings all of the data together in a common user-
interface. HIVToolbox allows virologists to use structural
information in their experimentation and structural biologists to
have easy access to functional information. Questions of inte-
rest that would have been virtually impossible to discern using the
existing data management are now readily apparent and ad-
dressable. We see no reason why HIVToolbox could not be used
to study the other HIV proteins and this integrative approach
should be readily adaptable to the study of more complex bio-
logical systems.
Availability and Future Directions
HIVToolbox is open access and can be found at http://
hivtoolbox.bio-toolkit.com. HIVToolbox can also be accessed
through links of HIV structures in the Protein Data Bank. The
application is platform independent, written in Java 2 Enterprise
Edition, JavaScript. The application is tested and supported
in Firefox 3.0 or higher. Other requirements include Java Run-
time Environment 1.6 or compatible browser plug-in capable of
running Java applets. Other browser such as Internet Explorer 7.0
or later, Google Chrome, Apple Safari work but some features
may not display as intended. HIVToolbox is free for academic use,
but a license is required for non-academic use.
In the future, we plan to integrate known drug binding sites
and drug resistance mutations into the database and the struc-
tural viewers. We also plan to update the database with more
minimotifs as they are annotated and the application will be
adapted to upload user-generated multiple sequence alignments. A
user registration feature will allow personalized displays and data
storage. We also plan in include an epidemiology module.
Methods
New structural models for Integrase
To generate structural models we used superposition back-
bone atoms of existing HIV-1 IN structures using Molmol;
superposition of all IN domains yielded RMSD of backbones
residues less than=0.4 A ˚ [36]. To create a model of the 3-domain
IN monomer, the catalytic domains of IN structures from 1EX4
(NTD and CCD) and 1K6Y (CCD and CTD) were superimposed
(called INTM) [8,10]. The CCD domains of two sets of mono-
mers were fit to the dimer structure of 1EX4 (called INTD).
Figure 9. Interactive protein display page for Tat in HIVToolbox. Sequence window, Structure windows, Log windows, and Sequence
Alignment section of HIVToolbox are shown. The interactive results page for HIV-1 tat is shown. The scrollable sequence window shows the protein
sequence, domains (with colored fonts), functional residues (highlighted), protein-protein interaction sites (thin lines under sequence), mapped
protein structures (thin colored lines over sequence) and minimotifs (figures under sequence). The synchronized interactive structural displays show
domains and selected minimotifs (left panel), functional sites and selected protein-protein interaction sites (center panel), and residues conserved at
or above a sequence conservation threshold selected with a slider or text box (right panel). The Sequence Alignment section shows alignment of a
representative set of 20 sequences with the RefSeq sequence and the structure sequence. A second tab reveals a position specific-scoring matrix of
amino acid frequencies at each position in the protein. More details about the features and use of HIVToolbox are in the supplement, and video
tutorials are at Bio-Toolkit [http://www.bio-toolkit.com].
doi:10.1371/journal.pone.0020122.g009
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domains of the 1K6Y tetramer (RMSD=0.4 A ˚; called INTT).
Finally, the CCDs of INTT were fit to the CCDs of 4IN:LEDGF
hetero-dimers (2B4J) to create an IN:LEDGF hetero-octamer
(called IN4L) [26]. In these models the domains of IN are tightly
packed and there is no observable van der Waals overlap between
atoms.
The NTD, CCD and CTD domains of HIV-1 and PFV IN
have highly similar folds, however the peptide linkers between
these domains are of different lengths and have different structures
[PDB: 1EX4, 1K6Y, 1WJA] [8,10,11,36]. We spatially fit the
HIV-1 IN domains to the PFV tetramer, without the interdomain
linkers. Since the PFV structure (3LQ2) is missing the NTD and
CTD in the second subunit of the dimer, we modeled these based
on the structure of the complete HPV monomer. This produced a
structural tetramer model of full length HIV-1 IN bound to two
ends of viral DNA (IN42). Superposition of the IN catalytic
domains in the IN:LEDGF structure complex (2B4J) to these
domains in IN42 yielded the IN:LEDGF hetero-octamer bound to
two viral DNAs (INL2).
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